Ogkologos

4396 ΔΗΜΟΣΙΕΥΣΕΙΣ 0 ΣΧΟΛΙΑ

Entrectinib Is Effective and Well Tolerated in Patients with Treatment-Naïve ROS1-positive...

Ogkologos - 19 Ιουλίου, 2024

FDA Approves Durvalumab with Chemotherapy for Mismatch Repair Deficient Primary Advanced...

Ogkologos - 19 Ιουλίου, 2024

Treating the Whole Person: How Cancer Centers Are Addressing Social Needs

Ogkologos - 18 Ιουλίου, 2024

One Year of Adjuvant T-DM1 Leads to Outstanding Long-Term Outcomes Among...

Ogkologos - 18 Ιουλίου, 2024

EMA Recommends Extension of Therapeutic Indications for Olaparib to Patients with...

Ogkologos - 17 Ιουλίου, 2024

PET-2-Guided BrECADD Better Tolerated and More Effective than eBEACOPP in Patients...

Ogkologos - 16 Ιουλίου, 2024

FDA Grants Accelerated Approval to Adagrasib with Cetuximab for KRAS G12C-mutated...

Ogkologos - 15 Ιουλίου, 2024

Second- or Third-Line Treatment with Tisotumab Vedotin Results in Greater Efficacy...

Ogkologos - 12 Ιουλίου, 2024

A Meaningful Benefit of the Quadruplet-Based Isatuximab Plus VRd Regimen in...

Ogkologos - 11 Ιουλίου, 2024

Lorlatinib Slows Growth of ALK-Positive Lung Cancers, May Prevent Brain Metastases

Ogkologos - 10 Ιουλίου, 2024

1...767778...440 Σελίδα 77 από 440

MOST POPULAR

Phlebotomist Breaks Into Ballet Performance In The Middle Of The Hospital

16 Σεπτεμβρίου, 2021

Similar Efficacy Between Subcutaneous and Intravenous Pembrolizumab Given with Chemotherapy for...

14 Απριλίου, 2025

SIOG 2020: New Research in Caring for and Treating People With...

12 Νοεμβρίου, 2020

EMA Recommends Granting a Conditional Marketing Authorisation for Zanidatamab

5 Ιουνίου, 2025

Φόρτωση περισσοτέρων

Entrectinib Is Effective and Well Tolerated in Patients with Treatment-Naïve ROS1-positive...

FDA Approves Durvalumab with Chemotherapy for Mismatch Repair Deficient Primary Advanced...

Treating the Whole Person: How Cancer Centers Are Addressing Social Needs

One Year of Adjuvant T-DM1 Leads to Outstanding Long-Term Outcomes Among...

EMA Recommends Extension of Therapeutic Indications for Olaparib to Patients with...

PET-2-Guided BrECADD Better Tolerated and More Effective than eBEACOPP in Patients...

FDA Grants Accelerated Approval to Adagrasib with Cetuximab for KRAS G12C-mutated...

Second- or Third-Line Treatment with Tisotumab Vedotin Results in Greater Efficacy...

A Meaningful Benefit of the Quadruplet-Based Isatuximab Plus VRd Regimen in...

Lorlatinib Slows Growth of ALK-Positive Lung Cancers, May Prevent Brain Metastases

MOST POPULAR

Phlebotomist Breaks Into Ballet Performance In The Middle Of The Hospital

Similar Efficacy Between Subcutaneous and Intravenous Pembrolizumab Given with Chemotherapy for...

SIOG 2020: New Research in Caring for and Treating People With...

EMA Recommends Granting a Conditional Marketing Authorisation for Zanidatamab

HOT NEWS

For Early-Stage Lung Cancer, Study Identifies Potential New Biomarker, Treatment Target

New on NCI Websites for June 2018

Adjuvant Multiagent Chemotherapy Regimens Associated with OS Benefit Following Resection of...

Cancer in My Community: Providing Supportive Care in Serbia

ΔΗΜΟΦΙΛΕΊΣ ΘΈΣΕΙΣ

ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ)

ΣΤΑΤΙΣΤΙΚΑ

ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ

ΔΗΜΟΦΙΛΗ ΚΑΤΗΓΟΡΙΑ